Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 1,196,000 shares at $36.82 ($43.4M) on 2025-01-29, disclosed to the SEC on 2025-01-30.
Scheduled sale ($43.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.29 | 326,932 | $11.9M | 27.3% |
| 2 | $36.29 | 326,932 | $11.9M | 27.3% |
| 3 | $36.34 | 269,068 | $9.8M | 22.5% |
| 4 | $36.34 | 269,068 | $9.8M | 22.5% |
| 5 | $36.82 | 4,000 | $147K | 0.3% |
| Total | $36.31 avg | 1,196,000 |
| $43.4M |
| 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |